|
|
|
 |
| What we do | How to apply | About us | News | Events | Clients | Contact Us | | HOME | |
 |
 |
 |
 |
 |
 |
Latest News |
|
Chromatide and Novasep
partnership extended to develop large scale synthesis technology May 25 2008 Chromatide and Novasep have extended their partnership, which was initiated in December 2006, to develop large scale solid phase peptide and oligonucleotide synthesis technology. Chromatide, an innovative IP driven company specialising in biosynthesis is backed by the Liverpool Seed Fund. Novasep, with its headuarters near Nancy (in Eastern France) is a leading partner for the pharmaceutical, food, cosmetics, agrochemicals and speciality chemicals industries through its two businesses Novasaep Process and novasep Synthesis. The aim of this continued partnership is to finalise co-development of a range of large scale peptide and oligonucleotide synthesis process, equipment and systems to meet the growing needs of biotechnology and pharmaceutical industries for more efficient, continuous flow instruments for gram to industrial scale production of high quality products. The interest of this partnership is to combine Chromatide's considerable experience in solid phase synthesis, specifically in the fields of peptide and oligonucleotide synthesis, to Novasep’ s expertise in synthesis services, chromatography, filtration and crystallisation technologies and processes in the biotechnology and pharmaceutical sectors to embrace pharmaceutical and biopharmaceutical industries’ challenges in obtaining pure peptides and oligonucleotides and to provide them with efficient solutions. Commenting on the announcement, Dr Don Wellings, Chromatide’s CSO, said, “We are delighted to be continuing to work with Novasep on this project”. He added, “The extension of our collaboration is illustrative of the success we have achieved to date on developing the synthesis systems which Novasep aim to launch in 2008. The relationship is enabling us to combine our expertise in developing peptide and oligonucleotide synthesis technologies, which includes production of novel resins and instrumentation, with the skills and knowledge Novasep has to accelerate development of much needed new systems. Novasep is a world leader in the market with well established relationships within the biotechnology and pharmaceutical sectors which will enable users’ rapid access to the technology we are co-developing”. Mr Jean Blehaut, President of Novasep Process Pharma Business Unit added, “The Chromatide team has many years experience in peptide and oligonucleotide synthesis and has excellent contacts with key thought leaders in this field and Novasep is the recognised leader of large scale chromatography applied to pharmaceuticals and biopharmaceuticals purification. Peptide manufacturers lack a cost efficient, automated solid phase synthesis technology, fully scalable from g to ton scale. We believe that this innovative technology resulting from our collaboration with Chromatide, combined with Novasep unparalleled chromatography and membrane technology portfolio will allow us to provide to our customers a unique, global process solution for peptide but also for oligonucléotides manufacturers”. www.chromatide.com
Ends For further information contact Gillian Hunt at Liverpool Ventures 0151 482 5533 *Alliance Fund Managers (AFM) is regulated by the FSA in the course of investment business Back to more Liverpool Ventures news
|
|
 |
 |
|
Liverpool Ventures
5th Floor, Cunard Building, Pier Head Liverpool L3 1DS Tel: 0151 236 0500 | 0151 236 4040 Fax: 0151 236 3060 email: info@liverpoolventures.com |
 |
 |
